Helex is extending the frontier of breakthrough gene editing-based therapeutics to meet the significant underserved medical needs of patients with genetic kidney diseases. Their pioneering EPIC-Cure™ technology ensures 3D genome-based drug design for higher precision while their proprietary lipid nanoparticle technology enables targeted delivery of genetic medicines to build a robust renal therapeutic pipeline.